Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abraxane, Carboplatin, and Bevacizumab in Triple Negative Metastatic Breast Cancer
NCT00479674Phase 2Completed
- Sponsor
- Duke University
- Start
- May 2007
- Primary completion
- Mar 2014
- Modality
- Polymer-based Nanoparticles, Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of nab-paclitaxel, bevacizumab, carboplatin in triple-negative breast cancer (TNBC), sponsored by Duke University. Started May 2007; status: completed.
02
Drugs
nab-paclitaxelbevacizumabcarboplatin
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT00479674.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00479674.